UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

Compared to the previous quarter, both analysts and management exhibited increased caution and a more defensive posture, particularly around guidance credibility and nonclinical revenue challenges.

Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

DGIST research team led by Yoonhee Lee and Gyogwon Koo enhances lung cancer diagnostic accuracy by combining exosome physical ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Baron Capital reports a standout 22.7% quarterly gain amid global turmoil. See how long-term focus beat the odds—and why it ...